Endorsement of SDCEP ‘Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw’ (March 2017)

We are now very pleased to announce the Department’s endorsement of the SDCEP 2017 guidance ‘Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw’ which updates and replaces SDCEP’s 2011 guidance ‘Oral Health Management of Patients Prescribed Bisphosphonates’. We believe that the recommendations, advice and information within this new guidance will be very helpful to support dental practitioners in their management of patients taking anti-resorptive or anti-angiogenic drugs. This guidance is mainly aimed at dentists in primary care dental practice, but will also be of relevance to the secondary care dental services, those involved in dental education, undergraduate trainees, prescribers and dispensers of these medicines, and patients taking these medicines.